Skip to main content
. Author manuscript; available in PMC: 2022 Jan 1.
Published in final edited form as: Cytotherapy. 2020 Oct 20;23(1):37–45. doi: 10.1016/j.jcyt.2020.09.003

Figure 4. N-803 pretreatment transiently exacerbates bm12-induced disease.

Figure 4.

C57BL/6 mice were given two injections of 200 μg/kg N-803 or IL-15 (Control) over span of 4 days prior to infusion of bm12 lymphocytes. Splenic CD45.1+ CXCR5+ PD-1+ CD4+ TFH, host CD19+ Fas+ GL7+ GC B cells, CD19+ CD138+ plasmablasts, and host CD45.2+ CD3+ CD8+ T cells as well as sera IgG and ANA titers were assessed (A) two weeks (n=8/group) or (B) three months (n=8–9/group) after disease initiation. ANA was only assessed in mice from whom sufficient quantity of blood was obtained. Similar results were obtained in two independent experimental replicates in A, while replicates were pooled in B.